S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
GLUE · Monte Rosa Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Monte Rosa Therapeutics Inc (GLUE)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$11.22
-0.14
(-1.23%)
● At close: October 21 at 4:00:00 PM EDT
$11.12
-0.10
(-0.89%)
Overnight:
9:01:06 PM EDT
DAY'S RANGE
$11.22
$11.10
$11.68
52-WEEK RANGE
$11.22
$8.94
$25.77
What's happening
- GLUE is down 1.23% today, trading at $11.22. — Live quote
- Volume today (63,271) is well below its 3-month average of 1,446,880. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.43 actual vs. $-0.39 estimated (-10.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 9
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (15 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
GLUE
-27.55%
vs S&P 500
-40.33%
1-YEAR RETURN
GLUE
+15.10%
vs S&P 500
+0.54%
6-MONTH RETURN
GLUE
-39.25%
3-MONTH RETURN
GLUE
-51.93%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.43
Est. $-0.39
MISS -10.6%
2026-04-26 (Q1 2026)
$-0.45
Est. $-0.39
MISS -16.1%
2026-01-26 (Q4 2025)
$-0.56
Est. $-0.36
MISS -56.2%
2025-10-26 (Q3 2025)
$-0.33
Est. $-0.38
BEAT +13.2%
Valuation Measures & Ratios
Enterprise Value4$867.1M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)33.32
Price / Book74.20
EV4 / Revenue30.18
EV4 / EBITDA51.49
Profit Margin-560.85%
Operating Margin-633.04%
Return on Equity (ROE8)-43.31%
Return on Assets (ROA9)-27.59%
Avg Volume (3M)1,446,880
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short19,686,241
Change from Prior Settlement+2.18%
% of Float—
Days to Cover (Short Ratio)18.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +15.1%. Finnhub market metrics ↗
- Latest SEC filing is Form 4, filed 2026-10-06; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -61.3% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -560.9%. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on GLUE
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$49.1M | -$50.0M | -$33.0M | -$15.6M | $44.0M | -$26.5M | -$32.6M | -$34.9M |
| Net income | -$43.4M | -$44.5M | -$27.1M | -$12.3M | $46.9M | -$23.9M | -$30.3M | -$32.0M |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $691.2M | $736.4M | $448.7M | $459.8M | $359.6M | $393.2M | $438.7M | $315.1M |
| Total liabilities | $203.9M | $214.5M | $215.6M | $214.0M | $91.5M | $118.0M | $215.8M | $109.6M |
| Stockholders' equity | $487.3M | $521.9M | $233.1M | $245.8M | $268.1M | $275.2M | $222.9M | $205.5M |
| Total current assets | $631.4M | $677.5M | $393.2M | $401.8M | $299.5M | $332.3M | $377.4M | $251.2M |
| Total current liabilities | $59.7M | $71.0M | $64.2M | $61.4M | $41.9M | $59.2M | $156.9M | $41.6M |
| Cash & equivalents | $90.1M | $159.9M | $129.9M | $208.3M | $69.4M | $78.5M | $224.3M | $125.6M |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $29.9M | $28.4M | $26.0M | $27.6M | $29.1M | $29.3M | $29.5M | $31.4M |
| Other non-current assets | $828.0K | $832.0K | $148.0K | $411.0K | $445.0K | $440.0K | $115.0K | $159.0K |
| Accounts payable | $7.2M | $7.9M | $3.5M | $14.5M | $5.6M | $6.5M | $17.2M | $4.0M |
| Accrued liabilities | $25.8M | $25.6M | $26.7M | — | — | — | $18.8M | — |
| Deferred revenue (current) | $22.1M | $33.1M | $29.6M | $24.8M | $18.4M | $32.6M | $117.2M | $18.9M |
| Other current liabilities | — | — | — | $1.7M | $1.5M | $4.4M | $3.4M | $1.3M |
| Common stock & paid-in capital | $9.0K | $8.0K | $7.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K |
| Retained earnings | -$565.1M | -$521.7M | -$477.2M | -$431.1M | -$404.0M | -$391.7M | -$438.6M | -$452.0M |
| Accumulated other comprehensive income (loss) | -$5.2M | -$4.7M | -$3.8M | -$3.2M | -$3.4M | -$3.3M | -$3.4M | -$2.3M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$44.1M | -$37.4M | -$43.0M | $100.4M | -$34.7M | -$45.5M | $128.9M | -$21.0M |
| Investing cash flow | -$28.9M | -$261.0M | -$65.1M | $38.1M | $25.3M | -$100.2M | -$30.9M | $37.7M |
| Financing cash flow | $3.2M | $328.3M | $29.6M | $348.0K | $365.0K | $14.0K | $608.0K | $15.0K |
| Free cash flow | -$48.8M | -$39.2M | -$43.8M | $99.8M | -$36.4M | -$47.1M | $128.7M | -$21.4M |
| Capital expenditures | $4.7M | $1.9M | $767.0K | $651.0K | $1.7M | $1.6M | $183.0K | $399.0K |
| Share-based compensation | $6.0M | $5.9M | $4.3M | $4.4M | $4.9M | $5.3M | $4.5M | $4.3M |
| Change in accounts receivable | — | — | — | — | $0 | — | — | — |
| Change in accounts payable | -$1.5M | $4.4M | -$10.6M | $8.9M | -$1.1M | -$10.9M | $13.3M | -$2.4M |
| Purchases of investments | $76.1M | $332.0M | $153.7M | $66.0M | $19.0M | $138.0M | $68.0M | $32.4M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$54.2M | -$81.1M | -$143.3M | -$112.4M | -$72.9M |
| Net income | -$38.6M | -$72.7M | -$135.4M | -$108.5M | -$74.0M |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $448.7M | $438.7M | $303.8M | $342.4M | $366.3M |
| Total liabilities | $215.6M | $215.8M | $124.5M | $71.0M | $18.8M |
| Stockholders' equity | $233.1M | $222.9M | $179.2M | $271.4M | $347.5M |
| Total current assets | $393.2M | $377.4M | $236.2M | $275.9M | $348.7M |
| Total current liabilities | $64.2M | $156.9M | $46.6M | $25.6M | $16.6M |
| Cash & equivalents | $129.9M | $224.3M | $128.1M | $54.9M | $346.1M |
| Property, plant & equipment | $26.0M | $29.5M | $33.8M | $27.1M | $12.3M |
| Other non-current assets | $148.0K | $115.0K | $352.0K | $278.0K | $0 |
| Accounts payable | $3.5M | $17.2M | $11.2M | $7.9M | $6.6M |
| Accrued liabilities | $26.7M | $18.8M | — | — | — |
| Deferred revenue (current) | $29.6M | $117.2M | $17.7M | $0 | — |
| Other current liabilities | — | $3.4M | $1.7M | $5.0M | $840.0K |
| Common stock & paid-in capital | $7.0K | $6.0K | $5.0K | $5.0K | $5.0K |
| Retained earnings | -$477.2M | -$438.6M | -$365.9M | -$230.5M | -$122.0M |
| Accumulated other comprehensive income (loss) | -$3.8M | -$3.4M | -$2.7M | -$1.8M | -$2.0M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$22.8M | $42.0M | -$43.8M | -$92.5M | -$59.4M |
| Investing cash flow | -$101.8M | -$44.5M | $88.8M | -$219.2M | -$9.7M |
| Financing cash flow | $30.4M | $98.9M | $27.5M | $20.5M | $377.6M |
| Free cash flow | -$27.5M | $38.0M | -$62.8M | -$105.4M | -$69.1M |
| Capital expenditures | $4.7M | $4.0M | $19.0M | $12.9M | $9.7M |
| Share-based compensation | $18.9M | $18.1M | $16.7M | $11.7M | $5.2M |
| Change in accounts payable | -$13.7M | $6.3M | $5.8M | -$744.0K | -$706.0K |
| Purchases of investments | $376.7M | $230.4M | $103.2M | $384.4M | $0 |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding GLUE as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers76.6%
Shares Outstanding101,478,945
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ | 8,861,171 | $214.4K | 8.73% | +31.9% | 2026-08-14 |
| NEA Management Company, LLC | 7,692,298 | $186.2M | 7.58% | +0.0% | 2026-08-14 |
| BlackRock, Inc. | 6,843,087 | $165.6M | 6.74% | +21.4% | 2026-08-07 |
| TCG Crossover Management, LLC | 4,622,151 | $111.9M | 4.55% | +0.0% | 2026-08-12 |
| Vestal Point Capital, LP | 4,600,000 | $111.3M | 4.53% | +27.7% | 2026-08-14 |
| BVF INC/IL | 4,460,886 | $108.0M | 4.40% | +0.0% | 2026-08-14 |
| BAKER BROS. ADVISORS LP | 4,345,736 | $105.2M | 4.28% | +0.0% | 2026-08-14 |
| State Street Corp | 3,731,416 | $90.3M | 3.68% | +11.3% | 2026-08-07 |
| MONTANOVA CAPITAL, LLC | 3,549,539 | $85.9M | 3.50% | -16.0% | 2026-08-14 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,412,927 | $82.6M | 3.36% | +10.1% | 2026-06-30 |
| Versant Venture Management, LLC | 3,180,780 | $77.0M | 3.13% | +0.0% | 2026-08-12 |
| BRAIDWELL LP | 2,451,562 | $59.3M | 2.42% | -23.5% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 1,864,113 | $45.1M | 1.84% | +21.0% | 2026-08-12 |
| AMERICAN CENTURY COMPANIES INC | 1,622,846 | $39.3M | 1.60% | -42.2% | 2026-08-12 |
| MARSHALL WACE, LLP | 1,593,600 | $38.6M | 1.57% | +11.2% | 2026-08-13 |
| Aisling Capital Management LP | 1,555,664 | $37.6M | 1.53% | +0.0% | 2026-08-13 |
| Bellevue Group AG | 1,190,000 | $28.8M | 1.17% | -4.8% | 2026-08-13 |
| DIMENSIONAL FUND ADVISORS LP | 1,177,488 | $28.5M | 1.16% | +13.1% | 2026-08-11 |
| MPM BioImpact LLC | 1,161,081 | $28.1M | 1.14% | -1.3% | 2026-08-14 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,108,295 | $26.8M | 1.09% | -44.6% | 2026-08-07 |
| Jupiter Topco LLC | 1,072,494 | $26.0M | 1.06% | +0.0% | 2026-08-14 |
| Frazier Life Sciences Management, L.P. | 1,000,000 | $24.2M | 0.99% | +0.0% | 2026-08-14 |
| Goldman Sachs Group Inc | 998,253 | $24.2M | 0.98% | -0.3% | 2026-08-14 |
| Woodline Partners LP | 962,884 | $23.3M | 0.95% | +1192.5% | 2026-08-14 |
| FMR LLC | 934,414 | $22.6M | 0.92% | -8.8% | 2026-08-13 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Insider activity is not available for this symbol right now.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 02:56 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-06 | 4 | 2026-10-05 | View on SEC.gov → |
| 2026-10-01 | 8-K | 2026-10-01 | View on SEC.gov → |
| 2026-09-08 | 8-K | 2026-09-08 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-07-17 | 4 | 2026-07-16 | View on SEC.gov → |
| 2026-07-16 | 4 | 2026-07-15 | View on SEC.gov → |
| 2026-07-07 | 4 | 2026-07-06 | View on SEC.gov → |
| 2026-07-06 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-07-01 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-06-30 | 4 | 2026-06-29 | View on SEC.gov → |
| 2026-06-30 | 4 | 2026-06-29 | View on SEC.gov → |
Recent news
Headlines about GLUE (Monte Rosa Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
GLUE261120P00005000 interactive stock chart | GLUE Nov 2026 5.000 put stock
Yahoo Finance UK · 2026-10-19 -
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Jumps 8% - Here's What Happened
MarketBeat · 2026-10-19 -
The Morning After: Jalen Ramsey is the glue to the Steelers’ defense
Behind the Steel Curtain · 2026-10-19 -
GLUE Nov 2026 5.000 put (GLUE261120P00005000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-19 -
(GLUE) Risk Channels and Responsive Allocation
Stock Traders Daily · 2026-10-17 -
GLUE Oct 2026 22.500 call (GLUE261016C00022500) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-17 -
Apple's new $79 iPhone Duo case requires actual glue to stay on your phone
PhoneArena · 2026-10-17 -
Monte Rosa Therapeutics Stock Price Forecast. Should You Buy GLUE?
StockInvest.us · 2026-10-16
No headlines in this category right now — try “All”.